Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2017-A02720-53 | Other Identifier | ID-RCB number, ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
B Lymphocytes are thought to play an important role in the pathophysiology of systemic sclerosis. In this study, the profibrosing role of B lymphocytes of patients with systemic sclerosis will be evaluated.
B Lymphocytes of patients with systemic sclerosis will be assessed in term of interaction with fibroblasts from patients with systemic sclerosis and compared to healthy controls.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patient with Scs | Experimental | patients with SSc, (10 diffuse forms and 20 limited forms) |
|
| healthy subject | Sham Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| skin biopsy | Procedure | A skin biopsy will be performed in 10 patients in the form of 2 punches of 5 mm in the injured area in aseptic condition with a Rodnan score. In this study, 10 skin biopsies are needed, and will be performed on the first 10 patients accepting this biopsy. |
| Measure | Description | Time Frame |
|---|---|---|
| Fibroblast transcriptomic : myofibroblast signature | expression of alpha Smooth Muscle Actin | 36 months |
| Measure | Description | Time Frame |
|---|---|---|
| Fibroblast transcriptomic | expression of COL1A1, COL1A2, COL3A1 by quantitative RT-PCR | 36 months |
| Difference in collagen infiltration by PicroSirius red staining between the skin biopsies of the two groups |
Not provided
Inclusion Criteria:
patients
Healthy "blood" and healthy "biopsy" controls
Exclusion Criteria:
patients
Healthy "blood" and healthy "biopsy" controls
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Launay, MD,PhD | University Hospital, Lille | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Claude Huriez, CHU | Lille | France |
Not provided
| ID | Term |
|---|---|
| D012595 | Scleroderma, Systemic |
| ID | Term |
|---|---|
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Blood punction | Other | 1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of B lymphocyte |
|
| 36 months |
| Difference in the inflammatory infiltrate by immunohistological markings between the skin biopsies of the two groups | 36 months |